Won So-Yoon, Kinney Sean M, Sefton Michael V
Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada.
Front Transplant. 2023 Oct 27;2:1244093. doi: 10.3389/frtra.2023.1244093. eCollection 2023.
Islet transplantation is a promising treatment for type I diabetes (T1D). Despite the high loss of islets during transplantation, current islet transplant protocols continue to rely on portal vein infusion and intrahepatic engraftment. Because of the risk of portal vein thrombosis and the loss of islets to instant blood mediated inflammatory reaction (IBMIR), other transplantation sites like the subcutaneous space have been pursued for its large transplant volume, accessibility, and amenability for retrieval. To overcome the minimal vasculature of the subcutaneous space, prevascularization approaches or vascularizing biomaterials have been used to subcutaneously deliver islets into diabetic mice to return them to normoglycemia. Previous vascularization methods have relied on a 4 to 6 week prevascularization timeframe. Here we show that a vascularizing MAA-coated silicone tube can generate sufficient vasculature in 2 to 3 weeks to support a therapeutic dose of islets in mice. In order to fully harness the potential of this prevascularized site, we characterize the unique, subcutaneous immune response to allogeneic islets in the first 7 days following transplantation, a critical stage in successful engraftment. We identify neutrophils as a specific cellular target, a previously overlooked cell in the context of subcutaneous allogeneic islet transplantation. By perioperatively depleting neutrophils, we show that neutrophils are a key, innate immune cell target for successful early engraftment of allogeneic islets in a prevascularized subcutaneous site.
胰岛移植是治疗I型糖尿病(T1D)的一种有前景的方法。尽管移植过程中胰岛损失率很高,但目前的胰岛移植方案仍继续依赖门静脉输注和肝内植入。由于存在门静脉血栓形成的风险以及胰岛会因即时血液介导的炎症反应(IBMIR)而损失,其他移植部位如皮下空间因其移植量大、易于操作和便于取出而受到关注。为了克服皮下空间血管稀少的问题,已采用血管预构方法或血管化生物材料将胰岛皮下递送至糖尿病小鼠体内,使其恢复正常血糖水平。先前的血管化方法依赖于4至6周的血管预构时间框架。在此,我们表明一种血管化的甲基丙烯酸酯包被硅胶管可在2至3周内生成足够的血管,以支持小鼠接受治疗剂量的胰岛。为了充分利用这个预先血管化部位的潜力,我们对移植后前7天内对异体胰岛的独特皮下免疫反应进行了表征,这是成功植入的关键阶段。我们确定中性粒细胞是一个特定的细胞靶点,在皮下异体胰岛移植背景下,这是一个此前被忽视的细胞。通过围手术期清除中性粒细胞,我们表明中性粒细胞是异体胰岛在预先血管化皮下部位成功早期植入的关键先天性免疫细胞靶点。